Fig. 2From: Clinical efficacy and molecular biomarkers in a phase II study of tucidinostat plus R-CHOP in elderly patients with newly diagnosed diffuse large B-cell lymphomaOutcomes of patients treated with CR-CHOP. a PFS and OS of all patients. b PFS and OS stratified by IPI. c PFS and OS stratified by cell of origin. CR-CHOP = tucidinostat (formerly known as chidamide), rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone. PFS = Progression-free survival. OS = Overall survival. IPI = International Prognostic IndexBack to article page